Enzyme Replacement Therapy Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes that causes a specific disease condition called lysosomal storage disease. Enzyme replacement therapy is used in Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzymes are obtained from sources such as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease. For instance, in order to address enzyme deficiency in Gaucher disease, modified version of glucocerebrosidase is administered intravenously every two weeks. Enzyme replacement is associated with fewer side effects than other treatment methods. However, enzyme replacement therapy may be inconvenient for some patients such as children and geriatric population due to intravenous administration. It may result in local infusion reaction or hypersensitive reactions in the form of local rash, fever, edema, bronchospasm or hypotension. Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1752 Market Dynamics Although lysosomal storage disease is a rare disorder, a significant number of people are affected with this disease. According to study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has incidence rate of 1 in 4000 to 1 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function. Being an orphan disease condition, regulatory agencies offer the benefit of rapid approval and ease in approval process. This in turn, is expected to expand the overall enzyme replacement therapy market with introduction of new therapies by various key players. For instance, in November 2017, The FDA approved Mepsevii (vestronidase alfa), which is first authorized treatment for pediatric and adult patients suffering from an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII). FDA granted Mepsevii with fast-track approval and orphan drug status to incentivize the development. Financial help by NGOs such as National Gaucher Society help patient receive enzyme replacement therapy that are costly. Regional Insights On the basis of geography, the global enzyme replacement therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to lead the market during forecast period, followed by Europe. According to study published in journal Hematology, in March 2017, incidence of Gaucher Disease in the general population varied from 0.39 to 5.80 per 100?000, and its prevalence varied from 0.70 to 1.75 per 100?000. Ease in access and government support for research and development is expected to aid growth of the enzyme replacement therapy market. Report includes chapters which deeply display the following deliverable about industry: • Enzyme Replacement Therapy Market Research Objective and Assumption • Enzyme Replacement Therapy Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Enzyme Replacement Therapy Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Enzyme Replacement Therapy Market, By Regions • Enzyme Replacement Therapy Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Enzyme Replacement Therapy Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Enzyme Replacement Therapy Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Enzyme Replacement Therapy Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Competitive Landscape Key players operating in the global enzyme replacement therapy market include Shire plc, Amicus Therapeutics, Genzyme Corporation, Pfizer Inc., BioMarin Pharmaceutical, Inc., Sigma-Tau Pharmaceuticals, Inc., Essential Pharmaceuticals Limited, Merck KGa, and AbbVie Inc. Market Taxonomy On the basis of enzyme type, the global enzyme replacement therapy market is segmented into -: • Agalsidase Beta • Velaglucerase Alfa • Imiglucerase • Taliglucerase • Alglucosidase Alfa • Laronidase • Idursulfase • Galsulfase • Pegademase • Others On the basis of indication, the global enzyme replacement therapy market is segmented into -: • Fabry Disease • Gaucher Disease • Pompe Disease • Scheie Syndrome • Hunter Disease • Maroteaux-Lamy Syndrome • Others Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/enzyme-replacement-therapy-market-1752 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes that causes a specific disease condition called lysosomal storage disease.
© Copyright 2024 Paperzz
